[NMR paper] Metabolomic NMR studies at presymptomatic and symptomatic stages of Huntington's disease on a Drosophila model.

[nmrlearner]

Metabolomic NMR studies at presymptomatic and symptomatic stages of Huntington's disease on a Drosophila model.

Related Articles Metabolomic NMR studies at presymptomatic and symptomatic stages of Huntington's disease on a Drosophila model.

J Proteome Res. 2020 Sep 03;:

Authors: Bertrand M, Decoville M, Meudal H, Birman S, Landon C

Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder, for which diagnostic development and discovery of new therapeutic targets are urgently required. In this study, a model of HD in Drosophila melanogaster has been used to identify metabolic biomarkers at presymptomatic and symptomatic stages of the disease. The pan-neuronal expression of a pathogenic fragment of the human Huntingtin (HTT) protein containing a 93-repeat polyglutamine expansion (Httex1p Q93) in transgenic flies induces a neuropathology with several characteristics of the human disease. The discriminant metabolites between the diseased flies and their controls were identified by 1H-nuclear magnetic resonance (NMR) and orthogonal partial least squares discriminant multivariate analysis (OPLS-DA). The experiments carried out with 10-day-old flies allowed us to identify a set of 10 biomarkers of the presymptomatic stage: NAD+, AMP, fumarate, asparagine, dimethylamine, ?-alanine, glutamine, succinate, glutamate and ethanol. Remarkably, the experiments conducted with 16-day-old flies, when the symptoms of the disease were present, highlighted a different set of 6 biomarkers: phosphocholine, ethanolamine, 2-oxoglutarate, succinate, pyruvate and acetate. Our results provide a better understanding of the metabolic impairments in a widely used HD model and demonstrate that metabolism perturbations change dramatically during the development of the disease.


PMID: 32880177 [PubMed - as supplied by publisher]



More...